In a recent systematic review, results from 20 TNF-α inhibitor de-escalation studies (14 RCTs and six non-RCTS) determining the actual reduction in the occurrence of adverse events when de-escalating the existing therapy in different inflammatory conditions, such as psoriasis, axSpA, RA, and IBD, were summarized. The gene discussed is TNF; the disease is inflammatory bowel disease.